Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07482657 Zelicapavir Respiratory Syncytial Virus Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07482657 clinical trial report covering Zelicapavir, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07485296 Pembrolizumab Recurrent Squamous Cell Carcinoma of the Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07485296 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120829 Recombinant human endostatin(The Children's Hospital) Advanced Malignant Thoracic Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
ChiCTR2600120829 clinical trial report covering Recombinant human endostatin(The Children's Hospital), Phase 2, endpoints, sponsor, geography, readout timi
Latest Hotspot
8 min read
NCT07486310 Doxorubicin Hydrochloride Advanced gastric carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07486310 clinical trial report covering Doxorubicin Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120859 Sintilimab Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
ChiCTR2600120859 clinical trial report covering Sintilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260955 Recombinant human interleukin-1 receptor antagonist(General Regeneratives) Arthritis, Gouty Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
CTR20260955 clinical trial report covering Recombinant human interleukin-1 receptor antagonist(General Regeneratives), Phase 2, endpoints, sponsor, geograp
Latest Hotspot
8 min read
ChiCTR2600120886 Pucotenlimab Laryngeal Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
ChiCTR2600120886 clinical trial report covering Pucotenlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07484724 JS-212 Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07484724 clinical trial report covering JS-212, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07485647 Lenalidomide Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07485647 clinical trial report covering Lenalidomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07484906 Psilocybin Suicidal Ideation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07484906 clinical trial report covering Psilocybin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07485010 Sulfamethoxazole/Trimethoprim Mycobacterium Abscessus Infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07485010 clinical trial report covering Sulfamethoxazole/Trimethoprim, Phase 2, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
NCT07487675 Sodium Valproate Temporomandibular Joint Dysfunction Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
26 August 2026
NCT07487675 clinical trial report covering Sodium Valproate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.